Core Viewpoint - Sunshine Nuohuo (688621.SH) aims to enhance its strategic layout in in vivo CAR-T cell therapy and nucleic acid drugs by investing 15 million yuan to subscribe for an additional registered capital of 110,556 yuan in Yuanma Zhiyao [1] Group 1: Company Overview - Yuanma Zhiyao is founded by a team of industry experts and returnee PhDs with diverse backgrounds, focusing on the innovation and research of circular mRNA in vivo CAR-T nucleic acid drugs [1] - The company aims to achieve "cell therapy effects" through "nucleic acid drug forms," intending to disrupt the commercialization challenges of CAR-T therapy [1]

Core Viewpoint - Yangguang Nuohuo (688621.SH) plans to invest 15 million yuan in Yuanma Zhiyao to increase its registered capital by 110,556 yuan, resulting in an 8.20% equity stake in the company. This move aims to advance the overall strategic layout in the fields of in vivo CAR-T cell therapy and nucleic acid drugs [1] Group 1 - The investment amount is 15 million yuan [1] - The registered capital increase is 110,556 yuan [1] - The resulting equity stake in Yuanma Zhiyao will be 8.20% [1] Group 2 - The strategic focus is on in vivo CAR-T cell therapy and nucleic acid drugs [1]